Clinical Evaluation of 5-Bromo-5-fluoro-6-methoxy-dihydro-2'-deoxy-uridine

J. J. Van Dyk, B. D. Clarkson, R. Duschinsky, O. Keller, E. La Sala, I. H. Krakoff

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


5-Bromo-5-fluoro-6-methoxy-dihydro-2’-deoxyuridine (MeOBrFUdR) was given to 22 patients with far-advanced, nonresectable neoplastic diseases. Of these, 16 received an adequate course of therapy. MeOBrFUdR produced biologic effects indistinguishable from those caused by 5-fluoro-2'-deoxyuridine (FUdR) at approximately equimolar doses. Two of the 16 patients showed significant therapeutic responses, a response rate that would be expected with FUdR. By biochemical and microbiologic methods, appreciable levels of FUdR were found to persist in the blood and urine of patients for 16 hours after administration of MeOBrFUdR, a much longer period than that following the administration of similar doses of FUdR. The persistence of detectable levels of FUdR in the blood did not result in increased toxicity of MeOBrFUdR as compared to FUdR.

Original languageEnglish
Pages (from-to)2129-2136
Number of pages8
JournalCancer Research
StatePublished - Nov 1967
Externally publishedYes


Dive into the research topics of 'Clinical Evaluation of 5-Bromo-5-fluoro-6-methoxy-dihydro-2'-deoxy-uridine'. Together they form a unique fingerprint.

Cite this